A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
I8F-MC-GPGA - ClinicalTrials.gov - NCT02759107
The 3 main purposes of this study are to determine the safety of tirzepatide and any side effects that might be associated with it, how much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it and how tirzepatide affects the levels of blood sugar. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.
Trial Summary
Age Range
21 - 70 yearsConditions the trial is for
Type 2 DiabetesWhat the trial is testing?
Dulaglutide, TirzepatideCould I receive a Placebo?
YesEnrollment Goal
142Trial Dates
May 11, 2016 - Jun 26, 2017How long will I be in the trial?
Your participation in part C could last approximately 12-14 weeks and include approximately 12 visits to the study center.Trial Phase
ILilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
You will complete the questionnaire on another website.YesNo